After eight daunting months of battling COVID-19, there may be some light at the end of the tunnel as two potential vaccine candidates recently announced promising test results. 

Vaccines from Pfizer and Moderna are similar in that they both use emerging technology called messenger ribonucleic acid (mRNA) to reach nearly 95 percent efficacy. Typically, scientists create vaccines by using live or inactivated virus cells, which puts the actual disease into a person’s body. However, with mRNA technology, Pfizer and Moderna were able to avoid that. MRNA carries coded instructions that tell cells what defenses are necessary by appearing as a threat. 

Of Course, There's a Catch

The use of the molecule is groundbreaking for a number of reasons. One is the speed at which the vaccines were developed. The other is that the use of mRNA means the vaccines contain no infectious COVID-19 properties that could get patients sick. 

However, there is a drawback to the vaccines: they have to be stored in brutally cold temperatures.

Under normal circumstances, vaccines can survive when stored at around 40 degrees Fahrenheit, but for Moderna, the vials must be stored at -4 degrees.

For Pfizer's vaccine, the threshold for keeping an effective dose is even steeper at a staggering -94 degrees. The icy temperatures are necessary to keep the mRNA molecule intact, otherwise it “begins to fall apart and twist around in ways so that it doesn’t become effective,” a representative for the pharmaceutical giant told Cheddar.

Vaccine Storage & Distribution Roadblock

With the need for cold storage comes the obstacle of how to pull off widespread distribution. Most hospitals in the U.S. do not house facilities that meet the requirements to store either the Moderna or Pfizer vaccines for extended periods. Both vaccines are able to survive in typical storing temperatures of 35 to 46 degrees, but their shelf lives are limited that way.

For Pfizer, the vaccine would no longer be effective after five days in normal storage temperatures. Moderna, meanwhile, shows more promise when it comes to effective distribution as it’s vaccines appear to remain effective for a month while stored 35 degrees.

Pfizer has come up with a plan to ship its vaccine in boxes filled with dry ice. The vials will remain protected for up to 15 days -- but the container can only be opened up to two times per day. 

This could be a logistical nightmare for parts of the world that don't have sufficient equipment - or enough dry ice - to keep the vaccines. Even in rural America, many hospitals don't have freezers that can keep doses cold enough, particularly for the Pfizer vaccine.  

Getting Vaccinated

So what does this mean for you? Once the FDA approves emergency use authorization of either one or both of the vaccines, it looks like they will likely be distributed first among populations that need it the most: frontline healthcare workers, the elderly, and those suffering from underlying health conditions. 

Like several existing vaccinations for other conditions, both Pfizer and Moderna require two rounds of treatment in order for the body to build up complete immunity. For those receiving the Pfizer vaccine, patients will need to return for a second dose after three weeks and for those getting the Moderna vaccine, they'll have to go back for round two after four weeks. 

Video produced by Ali Larkin. Article written by Lawrence Banton.

Share:
More In Science
UN Climate Report: Fossil Fuels are 'Choking Humanity'
In a nearly 3,700 page UN report, climate scientists outline the imminent dangers caused by climate change, saying fossil fuels are 'choking humanity.' The report calls some of the impacts of global warming 'irreversible,' warning of extreme consequences in the near future. Kristie L. Ebi, Professor of Global Health and Environmental and Occupational Health Sciences, University of Washington joined Cheddar's Opening Bell to discuss.
Fears of Potential for Climate Change Action Neglect Grow Amid Russia-Ukraine Tensions
World leaders are currently dealing with a handful of pressing issues, including Russia's invasion of Ukraine, inflation, and not to mention the COVID-19 pandemic; but it could be argued that the most pressing issue is one that has experienced its fair share of neglect in the past -- climate change. As tensions escalate between Russia and Ukraine, there is fear the focus on climate will once again be pushed aside. However, the White House appears to be making some effort to prevent that from happening. The White House Office of Science and Technology held a first-of-its-kind roundtable discussion with some of the nation's leading climate scientists on Thursday. Michael Mann, Director of the Earth System Science Center at Pennsylvania State University, and author of the book 'The New Climate War' joins Cheddar News' Closing Bell to discuss his experience as one of the climate scientists at the White House event.
NASA Veteran on New Telescope Program Looking at First Galaxies to Form in Universe
On December 25, 2021, NASA got into the holiday spirit by launching the James Webb Space Telescope, the largest and most powerful space science observatory in history. It is intended to succeed the Hubble Space Telescope as NASA's flagship mission in astrophysics and is able to view objects too old and distant for Hubble. Gregory Robinson, director of NASA's James Webb Space Telescope program, joins Cheddar News' Closing Bell to discuss the mission. "I think a lot of what we don't know today is what I'm expecting to find and certainly really understand what took place more than 13.5 billion years ago and see the formation of some of the first galaxies in our universe," said Robinson.
Leafly CEO on Big 2021 Cannabis Jobs Growth, Looking Ahead to NJ, NY Adult Use
Even amid the Great Resignation, the cannabis industry saw major job growth. As of January 2022, the legal industry supported more than 428,000 jobs — a 33 percent increase year-over-year, according to the sixth annual jobs report from Leafly, a website focused on cannabis use and education. Yoko Miyashita, CEO of Leafly, joined Cheddar News' Closing Bell to discuss. “You know we've got big moments coming ahead in New Jersey and New York with adult-use sales starting in New Jersey, hopefully by this fall, with New York quickly to follow," she said. "So we're hugely optimistic about the kind of job growth that those markets can drive with the right type of market setup.
Load More